Maria Ilenia De Bartolo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Ilenia De Bartolo has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Daniele Belvisi
Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
17 shared publications - Antonella Conte
IRCCS Neuromed Pozzilli Italy
16 shared publications - Giovanni Fabbrini
Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
15 shared publications - Alfredo Berardelli
Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy
13 shared publications - Giorgio Leodori
Sapienza University of Rome
10 shared publications - Matteo Costanzo
Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy
9 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
Continuous apomorphine infusion modulates cortical hyperexcitability and abnormal plasticity in Parkinson's disease
Background: Several studies have demonstrated the clinical benefit of apomorphine subcutaneous infusion in Parkinson's disease (PD). However, it remains unclear whether apomorphine infusion also modulates the abnormal motor cortical excitability and plasticity that contribute to PD pathophysiology and progression. Methods: We investigated the effects of continuous apomorphine infusion on cortical excitability and plasticity in patients with moderate-advanced PD, assessed at baseline and after 1, 12, and 24 weeks of treatment. Transcranial magnetic stimulation (TMS) was used to evaluate: i) motor cortex excitability (via input-output (I-O) recruitment curves and motor evoked potentials (MEPs) at 100–140% of resting motor threshold); ii) intracortical inhibition/facilitation (SICI; ICF), and plasticity using intermittent theta-burst stimulation (iTBS). Kinematic analysis of finger movements quantified bradykinesia. Eighteen healthy controls (HC) underwent baseline assessments for comparison. Results: At baseline, PD patients showed increased cortical excitability and reduced iTBS-induced plasticity compared to HC. After 24 weeks of continuous apomorphine infusion, cortical excitability decreased (reduced I-O slope and MEP amplitudes at 120–140% rMT), and plasticity improved (greater MEP facilitation 30 min post-iTBS). Clinically, motor and non-motor symptoms improved paralleled by a significant reduction in oral levodopa dose. Changes in excitability correlated with changes in motor performance. Conclusions: We found that continuous apomorphine infusion was associated with progressive modulation of selected cortical markers in PD, in parallel with clinical improvement. These findings also highlight the potential value of cortical markers for monitoring treatment response in advanced PD.
- 18 September 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
Open AccessContinuous apomorphine infusion modulates cortical hyperexcitability and abnormal plasticity in Parkinson's disease
Background: Several studies have demonstrated the clinical benefit of apomorphine subcutaneous infusion in Parkinson's disease (PD). However, it remains unclear whether apomorphine infusion also modulates the abnormal motor cortical excitability and plasticity that contribute to PD pathophysiology and progression. Methods: We investigated the effects of continuous apomorphine infusion on cortical excitability and plasticity in patients with moderate-advanced PD, assessed at baseline and after 1, 12, and 24 weeks of treatment. Transcranial magnetic stimulation (TMS) was used to evaluate: i) motor cortex excitability (via input-output (I-O) recruitment curves and motor evoked potentials (MEPs) at 100–140% of resting motor threshold); ii) intracortical inhibition/facilitation (SICI; ICF), and plasticity using intermittent theta-burst stimulation (iTBS). Kinematic analysis of finger movements quantified bradykinesia. Eighteen healthy controls (HC) underwent baseline assessments for comparison. Results: At baseline, PD patients showed increased cortical excitability and reduced iTBS-induced plasticity compared to HC. After 24 weeks of continuous apomorphine infusion, cortical excitability decreased (reduced I-O slope and MEP amplitudes at 120–140% rMT), and plasticity improved (greater MEP facilitation 30 min post-iTBS). Clinically, motor and non-motor symptoms improved paralleled by a significant reduction in oral levodopa dose. Changes in excitability correlated with changes in motor performance. Conclusions: We found that continuous apomorphine infusion was associated with progressive modulation of selected cortical markers in PD, in parallel with clinical improvement. These findings also highlight the potential value of cortical markers for monitoring treatment response in advanced PD.
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214778
Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is characterized by large-scale brain network dysfunctions. EEG microstate analysis may track these dynamics. We investigated whether microstates could distinguish patients with MS from healthy volunteers, and cognitively impaired from cognitively preserved (CP) patients. For this cross-sectional observational study, we recruited participants from the Policlinico Umberto I Multiple Sclerosis Center (Rome). We compared microstates of patients with relapsing-remitting MS (Expanded Disability Status Scale [EDSS] score p < 0.001), occurrence (p < 0.001), and coverage (p < 0.001) of class B (visual network) and reduced mean duration (MD) of classes F (salience network, p = 0.014) and G (sensorimotor network, p = 0.009). Topographic differences were found between cognitively impaired (n = 57, 20 women, mean age 35.5 years) and preserved (n = 31, 40 women, mean age 46.7 years) patients for classes C, F, and G (p < 0.05). Patients with cognitive impairment exhibited significantly reduced explained variance of class F (p = 0.003). Class A was associated with longer disease duration (explained variance, p = 0.006; MD, p = 0.042; coverage, p = 0.007), higher EDSS scores (MD, p = 0.013), and poorer ambulation (explained variance, p = 0.049). Class D inversely correlated with EDSS scores (occurrence, p = 0.011; coverage, p = 0.036), whereas class B inversely correlated with information processing speed (explained variance, p = 0.025; occurrence, p = 0.018; coverage, p = 0.028). Stepwise LDA identified classes B and D as discriminators between patients with MS and healthy volunteers (77% accuracy, p < 0.001), and class F as a discriminator between CP and impaired participants (64.8% accuracy, p = 0.007). EEG microstates reveal behaviorally relevant alterations in patients with MS, supporting their utility as sensitive markers of large-scale functional network reorganization associated with clinical disability.
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214778
Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is characterized by large-scale brain network dysfunctions. EEG microstate analysis may track these dynamics. We investigated whether microstates could distinguish patients with MS from healthy volunteers, and cognitively impaired from cognitively preserved (CP) patients. For this cross-sectional observational study, we recruited participants from the Policlinico Umberto I Multiple Sclerosis Center (Rome). We compared microstates of patients with relapsing-remitting MS (Expanded Disability Status Scale [EDSS] score p < 0.001), occurrence (p < 0.001), and coverage (p < 0.001) of class B (visual network) and reduced mean duration (MD) of classes F (salience network, p = 0.014) and G (sensorimotor network, p = 0.009). Topographic differences were found between cognitively impaired (n = 57, 20 women, mean age 35.5 years) and preserved (n = 31, 40 women, mean age 46.7 years) patients for classes C, F, and G (p < 0.05). Patients with cognitive impairment exhibited significantly reduced explained variance of class F (p = 0.003). Class A was associated with longer disease duration (explained variance, p = 0.006; MD, p = 0.042; coverage, p = 0.007), higher EDSS scores (MD, p = 0.013), and poorer ambulation (explained variance, p = 0.049). Class D inversely correlated with EDSS scores (occurrence, p = 0.011; coverage, p = 0.036), whereas class B inversely correlated with information processing speed (explained variance, p = 0.025; occurrence, p = 0.018; coverage, p = 0.028). Stepwise LDA identified classes B and D as discriminators between patients with MS and healthy volunteers (77% accuracy, p < 0.001), and class F as a discriminator between CP and impaired participants (64.8% accuracy, p = 0.007). EEG microstates reveal behaviorally relevant alterations in patients with MS, supporting their utility as sensitive markers of large-scale functional network reorganization associated with clinical disability.
- Open Access
Diagnostic Potential of Combined Skin Morphometric Analysis and Salivary Alpha-Synuclein Oligomers in Parkinson’s Disease
Oligomeric species of alpha-synuclein (α-syn) in saliva and phosphorylated α-syn deposits in the skin are established molecular biomarkers for Parkinson’s disease (PD). However, existing research has yet to fully explore the diagnostic potential of non-phosphorylated α-syn and other cutaneous morphometric parameters, such as variations in collagen type IV within the dermis and epidermis or α-syn expression in melanocytes. This study aims to evaluate and compare the diagnostic utility of these skin morphometric parameters in differentiating 32 PD patients from 19 healthy subjects (HSs), while also examining their correlation with salivary α-syn oligomer levels. Skin biopsies were analyzed via immunofluorescence and confocal microscopy, while salivary oligomeric α-syn was quantified through competitive ELISA. Results revealed a significant reduction in α-syn-positive fibres in PD patients compared to HSs (0.91; <0.0001). Conversely, the collagen staining area and the number of α-syn-positive melanocytes were significantly increased in the skin of PD patients. Specifically, the collagen type IV staining area was significantly higher in the dermis and surrounding the sweat glands of PD patients, demonstrating optimal diagnostic power (0.9448; <0.0001). Similarly, the increase in α-syn-positive melanocytes in PD patients showed robust diagnostic potential (0.84; <0.001). Salivary α-syn oligomers accurately discriminated between PD and HS groups. Furthermore, significant correlations were found between collagen type IV and melanocyte morphometric parameters and various clinical scores in PD. Our findings highlight how multimodal morphometric analysis of the skin can enhance diagnostic accuracy in PD, supporting the use of salivary and cutaneous biomarkers as complementary tools that may reflect distinct aspects of PD pathology.
Open AccessDiagnostic Potential of Combined Skin Morphometric Analysis and Salivary Alpha-Synuclein Oligomers in Parkinson’s Disease
Oligomeric species of alpha-synuclein (α-syn) in saliva and phosphorylated α-syn deposits in the skin are established molecular biomarkers for Parkinson’s disease (PD). However, existing research has yet to fully explore the diagnostic potential of non-phosphorylated α-syn and other cutaneous morphometric parameters, such as variations in collagen type IV within the dermis and epidermis or α-syn expression in melanocytes. This study aims to evaluate and compare the diagnostic utility of these skin morphometric parameters in differentiating 32 PD patients from 19 healthy subjects (HSs), while also examining their correlation with salivary α-syn oligomer levels. Skin biopsies were analyzed via immunofluorescence and confocal microscopy, while salivary oligomeric α-syn was quantified through competitive ELISA. Results revealed a significant reduction in α-syn-positive fibres in PD patients compared to HSs (0.91; <0.0001). Conversely, the collagen staining area and the number of α-syn-positive melanocytes were significantly increased in the skin of PD patients. Specifically, the collagen type IV staining area was significantly higher in the dermis and surrounding the sweat glands of PD patients, demonstrating optimal diagnostic power (0.9448; <0.0001). Similarly, the increase in α-syn-positive melanocytes in PD patients showed robust diagnostic potential (0.84; <0.001). Salivary α-syn oligomers accurately discriminated between PD and HS groups. Furthermore, significant correlations were found between collagen type IV and melanocyte morphometric parameters and various clinical scores in PD. Our findings highlight how multimodal morphometric analysis of the skin can enhance diagnostic accuracy in PD, supporting the use of salivary and cutaneous biomarkers as complementary tools that may reflect distinct aspects of PD pathology.
- Open Access
- 28 October 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (1) , 136-145
The impact of diet on Parkinson's disease risk: A data-driven analysis in a large Italian case-control population
Background: The role of dietary factors as risk or protective factors for Parkinson's disease (PD) remains debated. Objective: This retrospective case-control study aimed to evaluate the associations between foods identified through a data-driven analysis and PD, and to compare the relevance of dietary versus non-dietary factors as contributors to PD risk. Methods: The study included 680 PD patients and 612 matched controls recruited from six Italian neurology centers. Dietary data were collected using a validated 77-item food frequency questionnaire, and factor analysis was conducted to identify groups of correlated foods (i.e., factors). Logistic regression models were used to assess the associations between these factors and PD, while non-dietary factors were subsequently included in the model for comparison. Results: Seven factors were identified, four of which were significantly associated with PD. High consumption of sweets (Factor 1), red meat (Factor 3), and processed meats (Factor 6) was associated with an increased PD risk, whereas a high fruit intake (Factor 2) was protective. These associations remained significant after adjusting for other known non-dietary risk/protective factors. While the increased PD risk associated with dietary factors was weaker than that of non-dietary factors, protective dietary and non-dietary factors showed comparable effects in reducing PD risk. Conclusions: Data-driven analysis identified foods potentially influencing PD risk, although non-dietary factors demonstrated a greater impact on PD risk. These findings highlight the need to integrate both diet and lifestyle habits into future PD research and prevention strategies.
- 28 October 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (1) , 136-145
Open AccessThe impact of diet on Parkinson's disease risk: A data-driven analysis in a large Italian case-control population
Background: The role of dietary factors as risk or protective factors for Parkinson's disease (PD) remains debated. Objective: This retrospective case-control study aimed to evaluate the associations between foods identified through a data-driven analysis and PD, and to compare the relevance of dietary versus non-dietary factors as contributors to PD risk. Methods: The study included 680 PD patients and 612 matched controls recruited from six Italian neurology centers. Dietary data were collected using a validated 77-item food frequency questionnaire, and factor analysis was conducted to identify groups of correlated foods (i.e., factors). Logistic regression models were used to assess the associations between these factors and PD, while non-dietary factors were subsequently included in the model for comparison. Results: Seven factors were identified, four of which were significantly associated with PD. High consumption of sweets (Factor 1), red meat (Factor 3), and processed meats (Factor 6) was associated with an increased PD risk, whereas a high fruit intake (Factor 2) was protective. These associations remained significant after adjusting for other known non-dietary risk/protective factors. While the increased PD risk associated with dietary factors was weaker than that of non-dietary factors, protective dietary and non-dietary factors showed comparable effects in reducing PD risk. Conclusions: Data-driven analysis identified foods potentially influencing PD risk, although non-dietary factors demonstrated a greater impact on PD risk. These findings highlight the need to integrate both diet and lifestyle habits into future PD research and prevention strategies.
- Open Access
- 31 August 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (3) , 439-447
Opicapone in Parkinson’s disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit
Fluctuations often complicate the course of Parkinson’s disease (PD). The third-generation catechol- O -methyltransferase inhibitor, opicapone, is safe and effective in patients with PD motor fluctuations, whether long-standing or earlier onset. Real-world data are needed to identify the most appropriate candidates for initiating and sustaining therapy with opicapone. To evaluate the long-term outcomes and identify predictors for safer and prolonged use of opicapone. This real-world, longitudinal, multicenter, retrospective study collected data on the demographics, medical history, motor subtype, motor severity, cognitive and psychiatric disorders at baseline when opicapone was introduced as add-on therapy and at the last follow-up. Discontinuation rates and main causes were recorded. Clinical features of patients who continued/discontinued were compared to identify predictors for drug discontinuation and define successful long-term outcomes. Of the 178 enrolled patients, 85% (35% of them female) continued opicapone for a mean of 30.2 ± 19.64 months. The remaining 15% (13.4% female) discontinued opicapone within 8.9 ± 11.30 months due to disabling dyskinesia, hypotension, gastrointestinal disorders, or psychiatric disturbances. Continuers were younger at baseline than those who discontinued, but clinical-demographic features did not predict continuing opicapone therapy. Continuers had significantly lower Hoehn and Yahr scale scores and fewer night-time OFF periods compared with discontinuers, whereas levodopa equivalent daily dose and burden of motor and neuropsychiatric complications were similar. Continued opicapone therapy was associated with less motor impairment and reduced night-time OFF. Safety and long-term tolerability were higher in younger patients with a tendency to milder motor severity.
- 31 August 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (3) , 439-447
Open AccessOpicapone in Parkinson’s disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit
Fluctuations often complicate the course of Parkinson’s disease (PD). The third-generation catechol- O -methyltransferase inhibitor, opicapone, is safe and effective in patients with PD motor fluctuations, whether long-standing or earlier onset. Real-world data are needed to identify the most appropriate candidates for initiating and sustaining therapy with opicapone. To evaluate the long-term outcomes and identify predictors for safer and prolonged use of opicapone. This real-world, longitudinal, multicenter, retrospective study collected data on the demographics, medical history, motor subtype, motor severity, cognitive and psychiatric disorders at baseline when opicapone was introduced as add-on therapy and at the last follow-up. Discontinuation rates and main causes were recorded. Clinical features of patients who continued/discontinued were compared to identify predictors for drug discontinuation and define successful long-term outcomes. Of the 178 enrolled patients, 85% (35% of them female) continued opicapone for a mean of 30.2 ± 19.64 months. The remaining 15% (13.4% female) discontinued opicapone within 8.9 ± 11.30 months due to disabling dyskinesia, hypotension, gastrointestinal disorders, or psychiatric disturbances. Continuers were younger at baseline than those who discontinued, but clinical-demographic features did not predict continuing opicapone therapy. Continuers had significantly lower Hoehn and Yahr scale scores and fewer night-time OFF periods compared with discontinuers, whereas levodopa equivalent daily dose and burden of motor and neuropsychiatric complications were similar. Continued opicapone therapy was associated with less motor impairment and reduced night-time OFF. Safety and long-term tolerability were higher in younger patients with a tendency to milder motor severity.
- 14 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (2) , 452-462
Salivary biomarkers for the molecular diagnosis of dementia with Lewy bodies
Background: Despite dementia with Lewy bodies (DLB) being the second most common form of neurodegenerative dementia, more than 80% of DLB cases are initially misdiagnosed. Alpha-synuclein (a-syn) and tau species have been detected in peripheral tissues and biological fluids of DLB patients and among different biological fluids, saliva represent an easely accessible and non-invasive source for biomarker detection. Objective: This study aimed to investigate salivary a-syn and tau species as molecular disease biomarkers, assessing their potential in the diagnosis of DLB and in the differential diagnosis on respect to Alzheimer's disease (AD) and Parkinson's disease (PD). Methods: We measured total and oligomeric a-syn, total-tau, and S199-phosphorylated-tau (pS199-tau) in the saliva of 21 DLB, 20 AD, 20 PD patients, and 20 healthy subjects (HS) using quantitative enzyme-linked immunosorbent assay (ELISA) analyses. Results: Salivary total a-syn was not significantly changed between the different groups, whereas all pathological groups had a higher oligomeric a-syn concentration than HS. Salivary total-tau concentration was higher in all the pathological groups than HS, whereas the concentrations did not differ among patients’ groups. Conversely, salivary levels of pS199-tau was higher in DLB and AD patients than in HS and PD patients. Both correlation matrix and principal component analysis showed that core clinical DLB features were related to a-syn pathology, while cognitive decline was associated with salivary levels of pS199-tau in both DLB and AD patients. Receiver operating characteristic analysis reported high diagnostic accuracy for both a-syn oligomers and pS199-tau, between DLB and HS, and an adequate accuracy between DLB and PD. Conversely, the diagnostic accuracy was not optimal between DLB patients and AD patients. Conclusions: These findings provide preliminary evidence that salivary a-syn and tau species might be promising in identifying DLB patients on respect to PD patients and HS, while the diagnostic potential is limited on respect to AD.
- 14 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 104 (2) , 452-462
Salivary biomarkers for the molecular diagnosis of dementia with Lewy bodies
Background: Despite dementia with Lewy bodies (DLB) being the second most common form of neurodegenerative dementia, more than 80% of DLB cases are initially misdiagnosed. Alpha-synuclein (a-syn) and tau species have been detected in peripheral tissues and biological fluids of DLB patients and among different biological fluids, saliva represent an easely accessible and non-invasive source for biomarker detection. Objective: This study aimed to investigate salivary a-syn and tau species as molecular disease biomarkers, assessing their potential in the diagnosis of DLB and in the differential diagnosis on respect to Alzheimer's disease (AD) and Parkinson's disease (PD). Methods: We measured total and oligomeric a-syn, total-tau, and S199-phosphorylated-tau (pS199-tau) in the saliva of 21 DLB, 20 AD, 20 PD patients, and 20 healthy subjects (HS) using quantitative enzyme-linked immunosorbent assay (ELISA) analyses. Results: Salivary total a-syn was not significantly changed between the different groups, whereas all pathological groups had a higher oligomeric a-syn concentration than HS. Salivary total-tau concentration was higher in all the pathological groups than HS, whereas the concentrations did not differ among patients’ groups. Conversely, salivary levels of pS199-tau was higher in DLB and AD patients than in HS and PD patients. Both correlation matrix and principal component analysis showed that core clinical DLB features were related to a-syn pathology, while cognitive decline was associated with salivary levels of pS199-tau in both DLB and AD patients. Receiver operating characteristic analysis reported high diagnostic accuracy for both a-syn oligomers and pS199-tau, between DLB and HS, and an adequate accuracy between DLB and PD. Conversely, the diagnostic accuracy was not optimal between DLB patients and AD patients. Conclusions: These findings provide preliminary evidence that salivary a-syn and tau species might be promising in identifying DLB patients on respect to PD patients and HS, while the diagnostic potential is limited on respect to AD.
- 14 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (1) , e210192
Association of Early fMRI Connectivity Alterations With Different Cognitive Phenotypes in Patients With Newly Diagnosed Parkinson Disease
According to the dual syndrome hypothesis, patients with Parkinson disease (PD) with visuospatial deficits are more likely to progress to dementia, compared with patients with a prevalent dysexecutive syndrome. In this study, we aimed to investigate whether early connectivity changes in the dorsolateral prefrontal cortex (DLPFC) and the precuneus (PCun)-which are critical to fronto-executive and visuospatial functions, respectively-can identify distinct cognitive phenotypes in cognitively intact newly diagnosed patients with PD. Newly diagnosed, drug-naïve patients with PD (≤2 years from clinical onset) with normal Montreal Cognitive Assessment (MoCA), were consecutively enrolled from our Movement Disorders Clinics in Italy. Sex-matched and age-matched healthy controls (HCs) were enrolled among nonconsanguineous patients' relatives. Participants underwent 3T-fMRI to investigate resting-state functional connectivity (rs-FC) of DLPFC and PCun with a seed-based approach at baseline (T0). K-means cluster analysis was performed on z scores of rs-FC values of patients with PD to identify clusters of patients sharing common patterns of connectivity. Differences in neurophysiologic, motor, and nonmotor scales among PD clusters were assessed at T0 and after a 3.5-year follow-up (T1). The study included 68 patients with PD (27% women; mean age: 60 ± 9 years; Hoehn & Yahr score: 1.4 ± 0.5; MoCA score: 27.9 ± 1.6) and 31 HCs (39% women; mean age 64.2 ± 9.3 years) at T0. Forty-two patients completed T1 evaluation. Patients displayed reduced rs-FC of both DLPFC and PCun with several cortical and subcortical areas compared with HCs. Cluster 1 was defined by lower values of rs-FC in all investigated regions of interest while clusters 2 and 3, respectively, by higher and intermediate values. Despite none meeting criteria for mild cognitive impairment (MCI) at T0, cluster 1 was older and lower performing in global cognition, fronto-executive, and memory domains, compared with clusters 2 and 3 (all p < 0.031). At T1, a more evident worsening in global cognition, fronto-executive, and visuospatial domains and nonmotor and motor symptoms was observed in clusters 1 and 3 vs cluster 2 (all p < 0.04), with MCI being more frequent in clusters 1 and 3. Early connectivity changes of the DLPFC and the PCun occur in newly diagnosed patients with PD without MCI and can distinguish cognitive phenotypes, as confirmed after a longitudinal clinical observation.
- 14 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (1) , e210192
Association of Early fMRI Connectivity Alterations With Different Cognitive Phenotypes in Patients With Newly Diagnosed Parkinson Disease
According to the dual syndrome hypothesis, patients with Parkinson disease (PD) with visuospatial deficits are more likely to progress to dementia, compared with patients with a prevalent dysexecutive syndrome. In this study, we aimed to investigate whether early connectivity changes in the dorsolateral prefrontal cortex (DLPFC) and the precuneus (PCun)-which are critical to fronto-executive and visuospatial functions, respectively-can identify distinct cognitive phenotypes in cognitively intact newly diagnosed patients with PD. Newly diagnosed, drug-naïve patients with PD (≤2 years from clinical onset) with normal Montreal Cognitive Assessment (MoCA), were consecutively enrolled from our Movement Disorders Clinics in Italy. Sex-matched and age-matched healthy controls (HCs) were enrolled among nonconsanguineous patients' relatives. Participants underwent 3T-fMRI to investigate resting-state functional connectivity (rs-FC) of DLPFC and PCun with a seed-based approach at baseline (T0). K-means cluster analysis was performed on z scores of rs-FC values of patients with PD to identify clusters of patients sharing common patterns of connectivity. Differences in neurophysiologic, motor, and nonmotor scales among PD clusters were assessed at T0 and after a 3.5-year follow-up (T1). The study included 68 patients with PD (27% women; mean age: 60 ± 9 years; Hoehn & Yahr score: 1.4 ± 0.5; MoCA score: 27.9 ± 1.6) and 31 HCs (39% women; mean age 64.2 ± 9.3 years) at T0. Forty-two patients completed T1 evaluation. Patients displayed reduced rs-FC of both DLPFC and PCun with several cortical and subcortical areas compared with HCs. Cluster 1 was defined by lower values of rs-FC in all investigated regions of interest while clusters 2 and 3, respectively, by higher and intermediate values. Despite none meeting criteria for mild cognitive impairment (MCI) at T0, cluster 1 was older and lower performing in global cognition, fronto-executive, and memory domains, compared with clusters 2 and 3 (all p < 0.031). At T1, a more evident worsening in global cognition, fronto-executive, and visuospatial domains and nonmotor and motor symptoms was observed in clusters 1 and 3 vs cluster 2 (all p < 0.04), with MCI being more frequent in clusters 1 and 3. Early connectivity changes of the DLPFC and the PCun occur in newly diagnosed patients with PD without MCI and can distinguish cognitive phenotypes, as confirmed after a longitudinal clinical observation.
- Open Access
- 22 June 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (7) , 352
Interaction between α-Synuclein and Bioactive Lipids: Neurodegeneration, Disease Biomarkers and Emerging Therapies
The present review provides a comprehensive examination of the intricate dynamics between α-synuclein, a protein crucially involved in the pathogenesis of several neurodegenerative diseases, including Parkinson’s disease and multiple system atrophy, and endogenously-produced bioactive lipids, which play a pivotal role in neuroinflammation and neurodegeneration. The interaction of α-synuclein with bioactive lipids is emerging as a critical factor in the development and progression of neurodegenerative and neuroinflammatory diseases, offering new insights into disease mechanisms and novel perspectives in the identification of potential biomarkers and therapeutic targets. We delve into the molecular pathways through which α-synuclein interacts with biological membranes and bioactive lipids, influencing the aggregation of α-synuclein and triggering neuroinflammatory responses, highlighting the potential of bioactive lipids as biomarkers for early disease detection and progression monitoring. Moreover, we explore innovative therapeutic strategies aimed at modulating the interaction between α-synuclein and bioactive lipids, including the development of small molecules and nutritional interventions. Finally, the review addresses the significance of the gut-to-brain axis in mediating the effects of bioactive lipids on α-synuclein pathology and discusses the role of altered gut lipid metabolism and microbiota composition in neuroinflammation and neurodegeneration. The present review aims to underscore the potential of targeting α-synuclein-lipid interactions as a multifaceted approach for the detection and treatment of neurodegenerative and neuroinflammatory diseases.
- 22 June 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (7) , 352
Open AccessInteraction between α-Synuclein and Bioactive Lipids: Neurodegeneration, Disease Biomarkers and Emerging Therapies
The present review provides a comprehensive examination of the intricate dynamics between α-synuclein, a protein crucially involved in the pathogenesis of several neurodegenerative diseases, including Parkinson’s disease and multiple system atrophy, and endogenously-produced bioactive lipids, which play a pivotal role in neuroinflammation and neurodegeneration. The interaction of α-synuclein with bioactive lipids is emerging as a critical factor in the development and progression of neurodegenerative and neuroinflammatory diseases, offering new insights into disease mechanisms and novel perspectives in the identification of potential biomarkers and therapeutic targets. We delve into the molecular pathways through which α-synuclein interacts with biological membranes and bioactive lipids, influencing the aggregation of α-synuclein and triggering neuroinflammatory responses, highlighting the potential of bioactive lipids as biomarkers for early disease detection and progression monitoring. Moreover, we explore innovative therapeutic strategies aimed at modulating the interaction between α-synuclein and bioactive lipids, including the development of small molecules and nutritional interventions. Finally, the review addresses the significance of the gut-to-brain axis in mediating the effects of bioactive lipids on α-synuclein pathology and discusses the role of altered gut lipid metabolism and microbiota composition in neuroinflammation and neurodegeneration. The present review aims to underscore the potential of targeting α-synuclein-lipid interactions as a multifaceted approach for the detection and treatment of neurodegenerative and neuroinflammatory diseases.
- Open Access
- 28 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4823
Evaluating the Diagnostic Potential of Combined Salivary and Skin Biomarkers in Parkinson’s Disease
Oligomeric alpha-synuclein (α-syn) in saliva and phosphorylated α-syn deposits in the skin have emerged as promising diagnostic biomarkers for Parkinson’s disease (PD). This study aimed to assess and compare the diagnostic value of these biomarkers in discriminating between 38 PD patients and 24 healthy subjects (HSs) using easily accessible biological samples. Additionally, the study sought to determine the diagnostic potential of combining these biomarkers and to explore their correlations with clinical features. Salivary oligomeric α-syn levels were quantified using competitive ELISA, while skin biopsies were analyzed through immunofluorescence to detect phosphorylated α-syn at Ser129 (p-S129). Both biomarkers individually were accurate in discriminating PD patients from HSs, with a modest agreement between them. The combined positivity of salivary α-syn oligomers and skin p-S129 aggregates differentiated PD patients from HSs with an excellent discriminative ability with an AUC of 0.9095. The modest agreement observed between salivary and skin biomarkers individually suggests that they may reflect different aspects of PD pathology, thus providing complementary information when combined. This study’s results highlight the potential of utilizing a multimodal biomarker approach to enhance diagnostic accuracy in PD.
- 28 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4823
Open AccessEvaluating the Diagnostic Potential of Combined Salivary and Skin Biomarkers in Parkinson’s Disease
Oligomeric alpha-synuclein (α-syn) in saliva and phosphorylated α-syn deposits in the skin have emerged as promising diagnostic biomarkers for Parkinson’s disease (PD). This study aimed to assess and compare the diagnostic value of these biomarkers in discriminating between 38 PD patients and 24 healthy subjects (HSs) using easily accessible biological samples. Additionally, the study sought to determine the diagnostic potential of combining these biomarkers and to explore their correlations with clinical features. Salivary oligomeric α-syn levels were quantified using competitive ELISA, while skin biopsies were analyzed through immunofluorescence to detect phosphorylated α-syn at Ser129 (p-S129). Both biomarkers individually were accurate in discriminating PD patients from HSs, with a modest agreement between them. The combined positivity of salivary α-syn oligomers and skin p-S129 aggregates differentiated PD patients from HSs with an excellent discriminative ability with an AUC of 0.9095. The modest agreement observed between salivary and skin biomarkers individually suggests that they may reflect different aspects of PD pathology, thus providing complementary information when combined. This study’s results highlight the potential of utilizing a multimodal biomarker approach to enhance diagnostic accuracy in PD.
- Open Access
Exploring the Central Mechanisms of Botulinum Toxin in Parkinson’s Disease: A Systematic Review from Animal Models to Human Evidence
Botulinum toxin (BoNT) is an effective and safe therapy for the symptomatic treatment of several neurological disturbances. An important line of research has provided numerous pieces of evidence about the mechanisms of action of BoNT in the central nervous system, especially in the context of dystonia and spasticity. However, only a few studies focused on the possible central effects of BoNT in Parkinson’s disease (PD). We performed a systematic review to describe and discuss the evidence from studies focused on possible central effects of BoNT in PD animal models and PD patients. To this aim, a literature search in PubMed and SCOPUS was performed in May 2023. The records were screened according to title and abstract by two independent reviewers and relevant articles were selected for full-text review. Most of the papers highlighted by our review report that the intrastriatal administration of BoNT, through local anticholinergic action and the remodulation of striatal compensatory mechanisms secondary to dopaminergic denervation, induces an improvement in motor and non-motor symptoms in the absence of neuronal loss in animal models of PD. In human subjects, the data are scarce: a single neurophysiological study in tremulous PD patients found that the change in tremor severity after peripheral BoNT administration was associated with improved sensory–motor integration and intracortical inhibition measures. Further clinical, neurophysiological, and neuroimaging studies are necessary to clarify the possible central effects of BoNT in PD.
Open AccessExploring the Central Mechanisms of Botulinum Toxin in Parkinson’s Disease: A Systematic Review from Animal Models to Human Evidence
Botulinum toxin (BoNT) is an effective and safe therapy for the symptomatic treatment of several neurological disturbances. An important line of research has provided numerous pieces of evidence about the mechanisms of action of BoNT in the central nervous system, especially in the context of dystonia and spasticity. However, only a few studies focused on the possible central effects of BoNT in Parkinson’s disease (PD). We performed a systematic review to describe and discuss the evidence from studies focused on possible central effects of BoNT in PD animal models and PD patients. To this aim, a literature search in PubMed and SCOPUS was performed in May 2023. The records were screened according to title and abstract by two independent reviewers and relevant articles were selected for full-text review. Most of the papers highlighted by our review report that the intrastriatal administration of BoNT, through local anticholinergic action and the remodulation of striatal compensatory mechanisms secondary to dopaminergic denervation, induces an improvement in motor and non-motor symptoms in the absence of neuronal loss in animal models of PD. In human subjects, the data are scarce: a single neurophysiological study in tremulous PD patients found that the change in tremor severity after peripheral BoNT administration was associated with improved sensory–motor integration and intracortical inhibition measures. Further clinical, neurophysiological, and neuroimaging studies are necessary to clarify the possible central effects of BoNT in PD.